Population Pharmacokinetics and Pharmacodynamics of Apixaban Linking Its Plasma Concentration to Intrinsic Activated Coagulation Factor X Activity in Japanese Patients with Atrial Fibrillation.
Adult
Aged
Aged, 80 and over
Atrial Fibrillation
/ drug therapy
Factor Xa Inhibitors
/ administration & dosage
Female
Heart Failure
/ complications
Humans
Inhibitory Concentration 50
Japan
Male
Middle Aged
Models, Biological
Pyrazoles
/ administration & dosage
Pyridones
/ administration & dosage
Retrospective Studies
apixaban
cerebral infarction
heart failure
population pharmacokinetics and pharmacodynamics
Journal
The AAPS journal
ISSN: 1550-7416
Titre abrégé: AAPS J
Pays: United States
ID NLM: 101223209
Informations de publication
Date de publication:
24 06 2019
24 06 2019
Historique:
received:
12
03
2019
accepted:
12
06
2019
entrez:
26
6
2019
pubmed:
27
6
2019
medline:
22
7
2020
Statut:
epublish
Résumé
Apixaban is used in the prevention and treatment of patients with deep vein thrombosis or pulmonary embolism, and in the prevention of stroke or systemic embolism in patients with nonvalvular atrial fibrillation (AF). In this study, we aimed to elucidate intrinsic factors affecting efficacy of apixaban by conducting population pharmacokinetic and pharmacodynamic analysis using data from 81 Japanese AF patients. The intrinsic FXa activity was determined to assess the pharmacodynamic effect of apixaban. The pharmacokinetic and pharmacodynamic profiles were described based on a one-compartment model with first-order absorption and a maximum inhibitory model, respectively. Pharmacokinetic and pharmacodynamic analysis was conducted using a nonlinear mixed effect modeling program. The population pharmacokinetic parameters of apixaban were fixed at the reported values in our recent study. The population mean of half-maximal inhibitory concentration (IC
Identifiants
pubmed: 31236790
doi: 10.1208/s12248-019-0353-7
pii: 10.1208/s12248-019-0353-7
doi:
Substances chimiques
Factor Xa Inhibitors
0
Pyrazoles
0
Pyridones
0
apixaban
3Z9Y7UWC1J
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
80Références
Blood Coagul Fibrinolysis. 2015 Oct;26(7):844-7
pubmed: 26200653
Anal Biochem. 1976 May 7;72:248-54
pubmed: 942051
N Engl J Med. 2011 Mar 3;364(9):806-17
pubmed: 21309657
CPT Pharmacometrics Syst Pharmacol. 2018 Nov;7(11):728-738
pubmed: 30259707
J Pharmacokinet Pharmacodyn. 2003 Dec;30(6):387-404
pubmed: 15000421
Can J Cardiol. 2013 Jul;29(7 Suppl):S24-33
pubmed: 23790595
Nephron. 1976;16(1):31-41
pubmed: 1244564
AAPS J. 2015 Nov;17(6):1388-94
pubmed: 26112250
CPT Pharmacometrics Syst Pharmacol. 2014 Sep 17;3:e136
pubmed: 25229619
JAMA. 2001 Jun 13;285(22):2864-70
pubmed: 11401607
Europace. 2018 Oct 1;20(10):1577-1583
pubmed: 29186393
Comput Methods Programs Biomed. 2005 Sep;79(3):241-57
pubmed: 16023764
Thromb Haemost. 1995 Jul;74(1):7-17
pubmed: 8578528
Br J Clin Pharmacol. 2013 Feb;75(2):476-87
pubmed: 22759198
Circ J. 2011;75(8):1852-9
pubmed: 21670542
Pharmacogenet Genomics. 2017 Sep;27(9):329-336
pubmed: 28678049
Br J Clin Pharmacol. 2018 Jun;84(6):1301-1312
pubmed: 29457840
N Engl J Med. 2013 Feb 21;368(8):699-708
pubmed: 23216615
Clin Pharmacol Ther. 2010 Sep;88(3):375-82
pubmed: 20686477
Br J Clin Pharmacol. 2014 Oct;78(4):877-85
pubmed: 24697979
J Pharmacokinet Pharmacodyn. 2003 Dec;30(6):405-16
pubmed: 15000422
Thromb Res. 2002 Sep 1;107(5):223-8
pubmed: 12479882
Lancet. 1996 Sep 7;348(9028):633-8
pubmed: 8782752
Lancet. 2010 Mar 6;375(9717):807-15
pubmed: 20206776
N Engl J Med. 2011 Sep 15;365(11):981-92
pubmed: 21870978
J Med Chem. 2007 Nov 1;50(22):5339-56
pubmed: 17914785
N Engl J Med. 2010 Dec 23;363(26):2487-98
pubmed: 21175312
Drug Metab Pharmacokinet. 2013;28(1):59-70
pubmed: 22813718
N Engl J Med. 2011 Jul 14;365(2):147-56
pubmed: 21751907
Gastroenterology. 2014 Jul;147(1):109-118.e5
pubmed: 24704526
BMJ. 2016 Jun 15;353:i2868
pubmed: 27306620
J Clin Pharmacol. 2014 Aug;54(8):910-6
pubmed: 24706516
Int J Clin Pharmacol Ther. 2014 Jul;52(7):564-73
pubmed: 24725442
Br J Clin Pharmacol. 2013 Dec;76(6):908-16
pubmed: 23488672
N Engl J Med. 2013 Aug 29;369(9):799-808
pubmed: 23808982
Drug Metab Dispos. 2013 Apr;41(4):827-35
pubmed: 23382458
Br J Clin Pharmacol. 2013 Nov;76(5):776-86
pubmed: 23451769
Thromb Res. 2008;123(2):374-80
pubmed: 18486198
Coron Artery Dis. 2013 Sep;24(6):468-74
pubmed: 23787362
CPT Pharmacometrics Syst Pharmacol. 2017 May;6(5):340-349
pubmed: 28547774
Drug Metab Dispos. 2010 Mar;38(3):448-58
pubmed: 19940026
J Clin Invest. 1987 Dec;80(6):1527-34
pubmed: 2824564
Clin Pharmacol Ther. 2005 Oct;78(4):412-21
pubmed: 16198660